Credit: magicmine / Getty Images A comprehensive genomic profiling study involving more than 13,000 patients has shown that targetable G12C mutations in the KRAS oncogene are rare in genitourinary cancers, potentially limiting the role of routine testing and targeted treatment...
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) released new clinical data for its KRASG12C inhibitor BBO-8520, according to a company press release, showing response rates in non-small cell... BridgeBio Oncology Therapeutics (Nasdaq: BBOT) released new clinical data for its KRASG12C inhibitor BBO-8520,...
Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small-cell lung cancer (NSCLC) accounting for approximately 85% of cases [1]. Lung adenocarcinoma is the most common histological subtype of NSCLC and frequently harbors actionable driver alterations. KRAS mutations...
Jinfang Medicine-B (02595) announced that GFH375 has entered a Phase II study for first-line treatment of advanced non-small cell lung cancer (NSCLC) with KRAS G12D mutations. The study includes three treatment regimens: monotherapy, combination with an EGFR monoclonal antibody (cetuximab),...
“All patients who were response evaluable and had at least one post-baseline scan exhibited tumor shrinkage, and there were no patients that exhibited disease progression as their best overall response to treatment.” Ferdinandos Skoulidis, MD, PhD, MRCP, an associate professor...
